BofA moved to No Rating on Bluebird Bio (BLUE) after the company announced it has entered a definitive merger agreement under which Carlyle and SK Capital will acquire Bluebird Bio for about $30M in upfront cash, or $3 per share, in addition to $6.84 per share in a contingent value right.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BLUE:
- Cautious Hold Rating for Bluebird Bio Amid Strategic Shift and Uncertain Sales Milestones
- Bluebird Bio trading resumes
- Bluebird Bio trading halted, volatility trading pause
- Bluebird Bio downgraded to Neutral from Outperform at Baird
- Morning Movers: Bluebird Bio shares tumble following take-private deal
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue